Safety information

What "not approved" actually means

It is easy to read "not approved" as bureaucratic — a licence not yet granted for something that basically works. For most compounds discussed in this space, it means something more specific and more serious:

• No established safe dose. Dose-finding is what phase 1 and 2 trials do. Where those have not happened, no dose has been established as safe by anyone, and figures circulating online originate from people guessing.
• No characterised adverse effect profile. Rare but serious effects are found by studying thousands of people. A compound tested in 30 people, or none, has not had that done.
• No interaction data. Nobody has systematically studied what happens when it is combined with medicines you may already take.
• No long-term data. Effects that emerge over years are invisible in a 12-week study.

Animal evidence does not close these gaps. Over 90% of compounds that look promising in animals fail in human trials — usually for efficacy, sometimes for safety that animal models did not predict.

Sourcing risks

A compound bought outside a regulated supply chain carries a second set of risks entirely separate from the pharmacology:

• Identity. Independent testing of research-chemical products has repeatedly found contents that do not match the label — wrong compound, wrong quantity, or nothing active at all.
• Purity. Synthesis by-products, residual solvents and heavy metals are not removed unless someone is checking.
• Sterility. Anything injected must be sterile. Material not produced under pharmaceutical conditions is not, and a certificate of analysis showing purity says nothing about sterility or endotoxin content.
• Dose accuracy. Compounded and unlicensed versions of GLP-1 medicines have caused hospitalisations from dosing errors, prompting warnings from the MHRA and FDA.
• Certificates can be recycled. A CoA belongs to a specific batch. A PDF attached to a listing is not evidence about the vial you received.

Injection-related harm

Much of the serious harm seen clinically in this area has nothing to do with the compound. It comes from injecting:

• Infection. Abscesses, cellulitis and, less commonly, sepsis and endocarditis. These are treatable early and dangerous late.
• Blood-borne viruses. Hepatitis B, hepatitis C and HIV are transmitted by sharing any injecting equipment, including vials and water.
• Tissue damage. Scarring, lipoatrophy and nerve injury from repeated injection.
• Contaminated preparation. Reconstituting non-sterile material, or using non-sterile water, introduces contamination directly.

In the UK, needle and syringe programmes supply sterile equipment free and confidentially, to anyone, without judgement or a requirement to stop. They exist precisely because this harm is preventable. Find your nearest through NHS service search or ask any pharmacist.

Interactions and existing conditions

Interaction risk is where unapproved compounds most often cause avoidable harm, because neither you nor anyone else has the data.

• Diabetes medication. Anything affecting glucose regulation alongside insulin or sulfonylureas raises hypoglycaemia risk, which can be immediately dangerous.
• Thyroid history. GLP-1 and dual agonists are contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2.
• Pancreatitis or gallbladder disease. Both are reported with incretin agonists; prior history matters.
• Cardiovascular disease. Several compounds here affect heart rate or blood pressure.
• Cancer, current or past. Compounds that stimulate growth factor pathways or angiogenesis carry theoretical concerns that have not been resolved.
• Pregnancy or breastfeeding. Assume unsafe. Nothing here has been studied in pregnancy.
• Skin cancer risk or many moles. Directly relevant to melanocortin compounds, which alter pigmentation and can mask changes.

Warning signs worth acting on

Seek medical attention promptly for:

• Severe or persistent abdominal pain, particularly radiating to the back — possible pancreatitis
• Persistent vomiting, or inability to keep fluids down
• Fever, spreading redness, heat or swelling at an injection site
• Dark urine with muscle pain or weakness — possible rhabdomyolysis
• Chest pain, palpitations, breathlessness or fainting
• Sudden visual changes
• Yellowing of skin or eyes
• A mole that changes size, shape or colour, or a new pigmented lesion
• Signs of low blood sugar: shakiness, confusion, sweating, in anyone on diabetes medication

Talking to a doctor

People avoid telling clinicians because they expect judgement. In practice you are far more likely to get a practical conversation than a lecture, and the alternative — a doctor treating you without knowing what is in your system — is genuinely worse.

Useful things to bring:

• The compound name, and the vial or packaging if you have it
• How long you have been using it and when you last did
• Anything else you take, including prescribed medication and supplements
• What symptoms you have noticed and when they started

In the UK you can also speak to a pharmacist without an appointment, and NHS 111 will advise without involving anyone else.

Reducing risk

The lowest-risk option is not to use unapproved compounds. If that is not the decision you are making, these reduce harm meaningfully:

• Never share any equipment, including vials and water.
• Use sterile single-use equipment from a needle and syringe programme or pharmacy.
• Do not combine multiple compounds. Interaction risk compounds and attribution becomes impossible when something goes wrong.
• Tell someone what you are taking, so they can tell a clinician if you cannot.
• Do not use alone if it is the first time with a given compound.
• Keep the packaging and batch details.
• Stop and seek advice at the first sign of anything on the warning list above.
• If you have an existing condition or take prescribed medication, talk to a doctor first. This is the single highest-value thing on this list.

If you have a correction or think something here is wrong, tell us at research@genexishealth.uk. We would rather fix it.